The global Lovir-Class Active Pharmaceutical Ingredient (API) market size is predicted to grow from US$ 83.3 million in 2025 to US$ 107 million in 2031; it is expected to grow at a CAGR of 4.3% from 2025 to 2031.
Lovir-class API refers to the active pharmaceutical ingredients used in the formulation of antiviral drugs within the "lovir" category. These compounds are nucleoside or nucleotide analogues that inhibit viral DNA polymerase or other viral replication mechanisms, commonly used to treat herpesviruses, hepatitis B, and other viral infections.
United States market for Lovir-Class Active Pharmaceutical Ingredient (API) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Lovir-Class Active Pharmaceutical Ingredient (API) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Lovir-Class Active Pharmaceutical Ingredient (API) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Lovir-Class Active Pharmaceutical Ingredient (API) players cover Fuxiang Pharmaceuticals, Zhejiang Zhebei Pharmaceuticals, Hongyuan Pharmaceuticals, Xinxiang Pharmaceuticals, Hubei Yitai Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淟ovir-Class Active Pharmaceutical Ingredient (API) Industry Forecast鈥� looks at past sales and reviews total world Lovir-Class Active Pharmaceutical Ingredient (API) sales in 2024, providing a comprehensive analysis by region and market sector of projected Lovir-Class Active Pharmaceutical Ingredient (API) sales for 2025 through 2031. With Lovir-Class Active Pharmaceutical Ingredient (API) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Lovir-Class Active Pharmaceutical Ingredient (API) industry.
This Insight Report provides a comprehensive analysis of the global Lovir-Class Active Pharmaceutical Ingredient (API) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Lovir-Class Active Pharmaceutical Ingredient (API) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Lovir-Class Active Pharmaceutical Ingredient (API) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Lovir-Class Active Pharmaceutical Ingredient (API) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Lovir-Class Active Pharmaceutical Ingredient (API).
This report presents a comprehensive overview, market shares, and growth opportunities of Lovir-Class Active Pharmaceutical Ingredient (API) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Acyclovir
Valacyclovir
Penciclovir
Famciclovir
Other
Segmentation by Application:
Pharmaceuticals
Scientific Research
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Fuxiang Pharmaceuticals
Zhejiang Zhebei Pharmaceuticals
Hongyuan Pharmaceuticals
Xinxiang Pharmaceuticals
Hubei Yitai Pharmaceuticals
Chongqing Qingyang Pharmaceuticals
Zhejiang Chengyi Pharmaceuticals
Tianjin Junan Biopharmaceuticals
Shanghai Pharmaceuticals Kangli
Zhejiang Chetou Pharmaceuticals
Mangalam
Adrovent Pharma
Vinuthana
Atom pharma
Clearsynth
Key Questions Addressed in this Report
What is the 10-year outlook for the global Lovir-Class Active Pharmaceutical Ingredient (API) market?
What factors are driving Lovir-Class Active Pharmaceutical Ingredient (API) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Lovir-Class Active Pharmaceutical Ingredient (API) market opportunities vary by end market size?
How does Lovir-Class Active Pharmaceutical Ingredient (API) break out by Type, by Application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Lovir-Class Active Pharmaceutical Ingredient (API) Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Lovir-Class Active Pharmaceutical Ingredient (API) by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Lovir-Class Active Pharmaceutical Ingredient (API) by Country/Region, 2020, 2024 & 2031
2.2 Lovir-Class Active Pharmaceutical Ingredient (API) Segment by Type
2.2.1 Acyclovir
2.2.2 Valacyclovir
2.2.3 Penciclovir
2.2.4 Famciclovir
2.2.5 Other
2.3 Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Type
2.3.1 Global Lovir-Class Active Pharmaceutical Ingredient (API) Sales Market Share by Type (2020-2025)
2.3.2 Global Lovir-Class Active Pharmaceutical Ingredient (API) Revenue and Market Share by Type (2020-2025)
2.3.3 Global Lovir-Class Active Pharmaceutical Ingredient (API) Sale Price by Type (2020-2025)
2.4 Lovir-Class Active Pharmaceutical Ingredient (API) Segment by Application
2.4.1 Pharmaceuticals
2.4.2 Scientific Research
2.5 Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Application
2.5.1 Global Lovir-Class Active Pharmaceutical Ingredient (API) Sale Market Share by Application (2020-2025)
2.5.2 Global Lovir-Class Active Pharmaceutical Ingredient (API) Revenue and Market Share by Application (2020-2025)
2.5.3 Global Lovir-Class Active Pharmaceutical Ingredient (API) Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Lovir-Class Active Pharmaceutical Ingredient (API) Breakdown Data by Company
3.1.1 Global Lovir-Class Active Pharmaceutical Ingredient (API) Annual Sales by Company (2020-2025)
3.1.2 Global Lovir-Class Active Pharmaceutical Ingredient (API) Sales Market Share by Company (2020-2025)
3.2 Global Lovir-Class Active Pharmaceutical Ingredient (API) Annual Revenue by Company (2020-2025)
3.2.1 Global Lovir-Class Active Pharmaceutical Ingredient (API) Revenue by Company (2020-2025)
3.2.2 Global Lovir-Class Active Pharmaceutical Ingredient (API) Revenue Market Share by Company (2020-2025)
3.3 Global Lovir-Class Active Pharmaceutical Ingredient (API) Sale Price by Company
3.4 Key Manufacturers Lovir-Class Active Pharmaceutical Ingredient (API) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Lovir-Class Active Pharmaceutical Ingredient (API) Product Location Distribution
3.4.2 Players Lovir-Class Active Pharmaceutical Ingredient (API) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Lovir-Class Active Pharmaceutical Ingredient (API) by Geographic Region
4.1 World Historic Lovir-Class Active Pharmaceutical Ingredient (API) Market Size by Geographic Region (2020-2025)
4.1.1 Global Lovir-Class Active Pharmaceutical Ingredient (API) Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Lovir-Class Active Pharmaceutical Ingredient (API) Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Lovir-Class Active Pharmaceutical Ingredient (API) Market Size by Country/Region (2020-2025)
4.2.1 Global Lovir-Class Active Pharmaceutical Ingredient (API) Annual Sales by Country/Region (2020-2025)
4.2.2 Global Lovir-Class Active Pharmaceutical Ingredient (API) Annual Revenue by Country/Region (2020-2025)
4.3 Americas Lovir-Class Active Pharmaceutical Ingredient (API) Sales Growth
4.4 APAC Lovir-Class Active Pharmaceutical Ingredient (API) Sales Growth
4.5 Europe Lovir-Class Active Pharmaceutical Ingredient (API) Sales Growth
4.6 Middle East & Africa Lovir-Class Active Pharmaceutical Ingredient (API) Sales Growth
5 Americas
5.1 Americas Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Country
5.1.1 Americas Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025)
5.1.2 Americas Lovir-Class Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025)
5.2 Americas Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025)
5.3 Americas Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Region
6.1.1 APAC Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Region (2020-2025)
6.1.2 APAC Lovir-Class Active Pharmaceutical Ingredient (API) Revenue by Region (2020-2025)
6.2 APAC Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025)
6.3 APAC Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Lovir-Class Active Pharmaceutical Ingredient (API) by Country
7.1.1 Europe Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025)
7.1.2 Europe Lovir-Class Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025)
7.2 Europe Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025)
7.3 Europe Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Lovir-Class Active Pharmaceutical Ingredient (API) by Country
8.1.1 Middle East & Africa Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Country (2020-2025)
8.1.2 Middle East & Africa Lovir-Class Active Pharmaceutical Ingredient (API) Revenue by Country (2020-2025)
8.2 Middle East & Africa Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Type (2020-2025)
8.3 Middle East & Africa Lovir-Class Active Pharmaceutical Ingredient (API) Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Lovir-Class Active Pharmaceutical Ingredient (API)
10.3 Manufacturing Process Analysis of Lovir-Class Active Pharmaceutical Ingredient (API)
10.4 Industry Chain Structure of Lovir-Class Active Pharmaceutical Ingredient (API)
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Lovir-Class Active Pharmaceutical Ingredient (API) Distributors
11.3 Lovir-Class Active Pharmaceutical Ingredient (API) Customer
12 World Forecast Review for Lovir-Class Active Pharmaceutical Ingredient (API) by Geographic Region
12.1 Global Lovir-Class Active Pharmaceutical Ingredient (API) Market Size Forecast by Region
12.1.1 Global Lovir-Class Active Pharmaceutical Ingredient (API) Forecast by Region (2026-2031)
12.1.2 Global Lovir-Class Active Pharmaceutical Ingredient (API) Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Lovir-Class Active Pharmaceutical Ingredient (API) Forecast by Type (2026-2031)
12.7 Global Lovir-Class Active Pharmaceutical Ingredient (API) Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Fuxiang Pharmaceuticals
13.1.1 Fuxiang Pharmaceuticals Company Information
13.1.2 Fuxiang Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.1.3 Fuxiang Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Fuxiang Pharmaceuticals Main Business Overview
13.1.5 Fuxiang Pharmaceuticals Latest Developments
13.2 Zhejiang Zhebei Pharmaceuticals
13.2.1 Zhejiang Zhebei Pharmaceuticals Company Information
13.2.2 Zhejiang Zhebei Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.2.3 Zhejiang Zhebei Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Zhejiang Zhebei Pharmaceuticals Main Business Overview
13.2.5 Zhejiang Zhebei Pharmaceuticals Latest Developments
13.3 Hongyuan Pharmaceuticals
13.3.1 Hongyuan Pharmaceuticals Company Information
13.3.2 Hongyuan Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.3.3 Hongyuan Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Hongyuan Pharmaceuticals Main Business Overview
13.3.5 Hongyuan Pharmaceuticals Latest Developments
13.4 Xinxiang Pharmaceuticals
13.4.1 Xinxiang Pharmaceuticals Company Information
13.4.2 Xinxiang Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.4.3 Xinxiang Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Xinxiang Pharmaceuticals Main Business Overview
13.4.5 Xinxiang Pharmaceuticals Latest Developments
13.5 Hubei Yitai Pharmaceuticals
13.5.1 Hubei Yitai Pharmaceuticals Company Information
13.5.2 Hubei Yitai Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.5.3 Hubei Yitai Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Hubei Yitai Pharmaceuticals Main Business Overview
13.5.5 Hubei Yitai Pharmaceuticals Latest Developments
13.6 Chongqing Qingyang Pharmaceuticals
13.6.1 Chongqing Qingyang Pharmaceuticals Company Information
13.6.2 Chongqing Qingyang Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.6.3 Chongqing Qingyang Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Chongqing Qingyang Pharmaceuticals Main Business Overview
13.6.5 Chongqing Qingyang Pharmaceuticals Latest Developments
13.7 Zhejiang Chengyi Pharmaceuticals
13.7.1 Zhejiang Chengyi Pharmaceuticals Company Information
13.7.2 Zhejiang Chengyi Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.7.3 Zhejiang Chengyi Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Zhejiang Chengyi Pharmaceuticals Main Business Overview
13.7.5 Zhejiang Chengyi Pharmaceuticals Latest Developments
13.8 Tianjin Junan Biopharmaceuticals
13.8.1 Tianjin Junan Biopharmaceuticals Company Information
13.8.2 Tianjin Junan Biopharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.8.3 Tianjin Junan Biopharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Tianjin Junan Biopharmaceuticals Main Business Overview
13.8.5 Tianjin Junan Biopharmaceuticals Latest Developments
13.9 Shanghai Pharmaceuticals Kangli
13.9.1 Shanghai Pharmaceuticals Kangli Company Information
13.9.2 Shanghai Pharmaceuticals Kangli Lovir-Class Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.9.3 Shanghai Pharmaceuticals Kangli Lovir-Class Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Shanghai Pharmaceuticals Kangli Main Business Overview
13.9.5 Shanghai Pharmaceuticals Kangli Latest Developments
13.10 Zhejiang Chetou Pharmaceuticals
13.10.1 Zhejiang Chetou Pharmaceuticals Company Information
13.10.2 Zhejiang Chetou Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.10.3 Zhejiang Chetou Pharmaceuticals Lovir-Class Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Zhejiang Chetou Pharmaceuticals Main Business Overview
13.10.5 Zhejiang Chetou Pharmaceuticals Latest Developments
13.11 Mangalam
13.11.1 Mangalam Company Information
13.11.2 Mangalam Lovir-Class Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.11.3 Mangalam Lovir-Class Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Mangalam Main Business Overview
13.11.5 Mangalam Latest Developments
13.12 Adrovent Pharma
13.12.1 Adrovent Pharma Company Information
13.12.2 Adrovent Pharma Lovir-Class Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.12.3 Adrovent Pharma Lovir-Class Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Adrovent Pharma Main Business Overview
13.12.5 Adrovent Pharma Latest Developments
13.13 Vinuthana
13.13.1 Vinuthana Company Information
13.13.2 Vinuthana Lovir-Class Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.13.3 Vinuthana Lovir-Class Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Vinuthana Main Business Overview
13.13.5 Vinuthana Latest Developments
13.14 Atom pharma
13.14.1 Atom pharma Company Information
13.14.2 Atom pharma Lovir-Class Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.14.3 Atom pharma Lovir-Class Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Atom pharma Main Business Overview
13.14.5 Atom pharma Latest Developments
13.15 Clearsynth
13.15.1 Clearsynth Company Information
13.15.2 Clearsynth Lovir-Class Active Pharmaceutical Ingredient (API) Product Portfolios and Specifications
13.15.3 Clearsynth Lovir-Class Active Pharmaceutical Ingredient (API) Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Clearsynth Main Business Overview
13.15.5 Clearsynth Latest Developments
14 Research Findings and Conclusion
听
听
*If Applicable.
